Cantor Fitzgerald Maintains Overweight on Immunovant, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen maintains an Overweight rating on Immunovant (NASDAQ:IMVT) and raises the price target from $30 to $45.
October 16, 2023 | 4:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Immunovant and raised the price target from $30 to $45, indicating a positive outlook for the company.
The raised price target by Cantor Fitzgerald indicates a positive outlook for Immunovant. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100